DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20150392

A prospective study on sleep disorders related to antidepressant drugs use in a tertiary care teaching hospital

Farhan Ahmad Khan, Kirti Vishwakarma, Vishal P. Giri, Chitrak Bansal

Abstract


Background: Prescription of antidepressants has been increased from the last decade and responsible for producing sleep disorders as adverse drug reactions (ADRs). Sleep disorders can be divided into 3 large groups: (1) insomnia, (2) primary complaint of daytime sleepiness, and (3) Association of disruptive behaviours during sleep, the disorders of arousal. So active surveillance is needed to access these ADRs.

Aims and Objective: To analyze the sleep disturbances as ADRs of various antidepressants prescribed to the patients attending psychiatry outpatient department (OPD).

Methods: This prospective study was conducted on patients aged ≤74 years attending Department of Psychiatry OPD and were prescribed Antidepressants for the duration of 8 months (December, 2013-July, 2014). The ADRs reported were confirmed by WHO UMC Causality Assessment Scale.

Results: Total number of patients enrolled on the basis of inclusion and exclusion criteria (n=50). Total number of ADRs related to drugs prescribed were found to be n=69. Total number of patients with sleep disturbances as ADRs were found to be n=28.

Conclusion: The drug, most frequently implicated to cause sleep disturbances, was mirtazapine. Increased sleep was the most common ADR, found to occur. Unusual ADRs such as sleep talking was also seen.


Keywords


Sleep disturbances, Antidepressants, Mirtazapine

Full Text:

PDF

References


Reite ML, Nagel KE, Ruddy JR. The Evaluation and Management of Sleep Disorders. Washington, DC: American Psychiatric Press; 1990.

American Sleep Disorders Association. In: Thorpy MJ, editor. The International Classification of Sleep Disorders: Diagnosis and Coding Manual. Lawrence, Kansas: Allen Press; 1990.

National Centre for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD: National Centre for Health Statistics; 2011.

Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65(7):927-47.

Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci. 2003;4(2):121-30.

Winokur A, DeMartinis NArd, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64(10):1224-9.

Gillin JC, Jernajczyk W, Valladares-Neto DC, Golshan S, Lardon M, Stahl SM. Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl). 1994;116(4):433-6.

Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol. 1995;10 Suppl 4:11-7.

Casper RC, Katz MM, Bowden CL, Davis JM, Koslow SH, Hanin I. The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. J Affect Disord. 1994;31(3):151-64.

Kerr JS, Fairweather DB, Hindmarch I. Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients. Int Clin Psychopharmacol. 1993;8(4):341-3.

Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski VJ, Wilson MJ, et al. Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry. 1991;29(1):23-40.

Shipley JE, Kupfer DJ, Griffin SJ, Dealy RS, Coble PA, McEachran AB, et al. Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients. Psychopharmacology (Berl). 1985;85(1):14-22.

Wolf R, Dykierek P, Gattaz WF, Maras A, Kohnen R, Dittmann RW, et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry. 2001;34(2):60-5.

Hicks JA, Argyropoulos SV, Rich AS, Nash JR, Bell CJ, Edwards C, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry. 2002;180:528-35.

Jindal RD, Friedman ES, Berman SR, Fasiczka AL, Howland RH, Thase ME. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol. 2003;23(6):540-8.

Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56(6):229-37.

Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety. 1999;9(2):54-60.

Guelfi JD, Ansseau M, Timmerman L, Kørsgaard S, Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21(4):425-31.

Ridout F, Meadows R, Johnsen S, Hindmarch I. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol Clin Exp 2003;18(4):261-69.

Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr, Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10(5):541-50.